Screening, Brief Intervention and Referral to Treatment or Prevention (SBIRT/P) for alcohol, tobacco, and other drugs (ATOD) use and misuse in adult populations that experience health disparities (R01
Can you apply?
This grant is for research organizations and institutions studying SBIRT/P interventions for substance use in health-disparate adult populations. Eligible applicants include research institutions, universities, hospitals, and nonprofit organizations with research capacity. The program supports NIH R01 grants requiring clinical trial design and implementation. Geographic scope is nationwide, though research must address alcohol, tobacco, and other drug (ATOD) use disparities in underserved populations.
Applicants must demonstrate institutional research infrastructure and Institutional Review Board (IRB) capacity. The project must include a clinical trial component. Preference exists for research serving populations experiencing health disparities in substance use treatment access or outcomes.
This grant is for research organizations and institutions studying SBIRT/P interventions for substance use in health-disparate adult populations. Eligible applicants include research institutions, universities, hospitals, and nonprofit organizations with research capacity. The program supports NIH R01 grants requiring clinical trial design and implementation. Geographic scope is nationwide, though research must address alcohol, tobacco, and other drug (ATOD) use disparities in underserved populations.
Applicants must demonstrate institutional research infrastructure and Institutional Review Board (IRB) capacity. The project must include a clinical trial component. Preference exists for research serving populations experiencing health disparities in substance use treatment access or outcomes.
Program description
The Office of Disease Prevention (ODP) and participating National Institutes of Health (NIH) Institutes, Centers, and Offices (ICOs) are issuing this notice of funding opportunity (NOFO) seeking applications to test innovative approaches to implementing SBIRT/P for alcohol, tobacco, and other drugs (ATOD) use and misuse in adult populations that experience health disparities. SBIRT/P, (a term used for purposes of this funding announcement), involves screening individuals for risk of ATOD use and misuse, briefly intervening with a conversation about harmful substance use, and referring individuals for treatment or preventive services, as needed.
Proposed research should include prospective tests of SBIRT/P and should leverage collaborations with healthcare and community partners. Specific research interests of participating NIH ICOs are detailed within.
Who can apply
Eligible applicants
- 501(c)(3) Public Charity
- City / Municipal Government
- County Government
- Hospital
- Nonprofits
- Private University
- Public Authority
- Public K-12 School
- Public University
- Small Business (SBA-defined)
- Special District
- State Government
- Tribal Nation
- Tribal Organization
Demographic focus
Details
This grant is for research organizations and institutions studying SBIRT/P interventions for substance use in health-disparate adult populations. Eligible applicants include research institutions, universities, hospitals, and nonprofit organizations with research capacity. The program supports NIH R01 grants requiring clinical trial design and implementation. Geographic scope is nationwide, though research must address alcohol, tobacco, and other drug (ATOD) use disparities in underserved populations.
Applicants must demonstrate institutional research infrastructure and Institutional Review Board (IRB) capacity. The project must include a clinical trial component. Preference exists for research serving populations experiencing health disparities in substance use treatment access or outcomes.
How to apply
Application links
Required documents
- SF-424 (R&R) form
- Project Narrative (research plan)
- Detailed Budget and Budget Justification
- Biosketches (senior personnel)
- Institutional Review Board (IRB) approval or IRB protocol
- Letters of institutional support and commitment
- Data Safety Monitoring Plan (clinical trial required)
- Human Subjects Protection section
- Preliminary data or progress reports
Program contact
- 👤 National Institutes of Health
- 📧 grantsinfo@nih.gov
- 📞 301-402-2541
Funding track record
Recent awards under CFDA 93.307 from the last 3 years — real organizations that won funding through this same program.
Top 10 Largest Recent Awards
-
$57,145,935
-
$48,558,256
-
$43,100,665
-
$41,925,783
-
$41,194,375
-
$38,870,836
-
$37,142,240
-
$35,966,257
-
$35,161,090
-
$34,649,979
Top States by Funding
- CA 9 awards $245.6M
- NC 4 awards $112.1M
- TX 5 awards $81.8M
- NY 5 awards $80.8M
- GA 3 awards $75.2M
Source: USAspending.gov — federal spending transparency. Data covers last 3 years.
FAQ
Who can apply for this SBIRT/P R01 grant?
Research institutions, universities, hospitals, and nonprofit organizations with research capacity and IRB approval processes. Applicants must have experience conducting clinical research and substance use interventions.
What is the typical application deadline?
The next fixed deadline is May 7, 2027. Check NIH's Grants.gov portal for rolling submission dates and any resubmission windows.
Must my project include a clinical trial?
Yes, this funding announcement explicitly requires a clinical trial component. Your research design must include human subjects and rigorous outcome measurement.
How competitive is this funding?
NIH R01 grants are highly competitive. Success rates typically range 10-20%. Strong preliminary data and experienced teams significantly improve chances.
What is the typical funding range?
R01 grants vary widely. Review NIH estimates for your institute type and state on the NIH website, but total costs often range from $250K-$750K annually.
💡 Tips for applicants
- Build partnerships with healthcare settings serving health-disparate populations early. Engaged partner organizations strengthen applications and show implementation feasibility.
- Include robust preliminary data from your own SBIRT/P interventions. Reviewers expect evidence your approach works before funding a full trial.
- Address health disparities explicitly. Explain which populations you serve, why they face barriers, and how your intervention reduces gaps.
- Design a rigorous, feasible clinical trial. Include clear inclusion/exclusion criteria, randomization strategy, and validated outcome measures for substance use reduction.
- Secure IRB approval and institutional commitment letters before submission. NIH expects evidence your institution supports the research infrastructure needed.
⚠️ Common mistakes
Weak or missing preliminary data from prior SBIRT/P work undermines credibility. Reviewers doubt whether your team can execute a clinical trial without evidence of prior success.
Vague health disparities framing fails to connect population characteristics to actual substance use barriers. Be specific about which disparities your study addresses and why your intervention targets them.
Underestimating feasibility challenges in recruiting and retaining health-disparate populations in clinical trials. Include realistic recruitment timelines and retention strategies based on similar populations.
Similar grants
- OPEN 27-0343-10 FFY27 Local Agency General Non-Enforcement — Illinois Department of Transportation
- ROLLING Annual Agency Threshold Application Applicants for Funding Start Here — Texas City of Austin - Austin Public Health
- CLOSED Virginia’s Black Indigenous and People of Color (BIPOC) Grant – FY26 — Virginia The Virginia Department of Historic Resources
- ROLLING RTAP Grant Program (Rolling) — Virginia Department of Rail and Public Transportation
- ROLLING Rail Industrial Access Grant (RIA) — Virginia Department of Rail and Public Transportation